Genome-wide association studies (GWAS) have revealed important biological insights into
complex diseases, which are broadly expected to lead to the identification of new drug …

The development of new drugs has become challenging as the necessary investments in
time and money have increased while drug approval rates have decreased. A potential …

Drug repurposing has attracted increased attention, especially in the context of drug
discovery rates that remain too low despite a recent wave of approvals for biological …

Over the past few years, large investments have been made in genome-wide association
studies (GWAS) with the expectation that some of these studies would lead to the …

Target identification (determining the correct drug targets for a disease) and target validation
(demonstrating an effect of target perturbation on disease biomarkers and disease end …

In a pair of papers in this issue of Science Translational Medicine, Butte et al. provide a
concrete example of how reinterpreting and comparing genome-wide metrics allows us to …

Discovering novel uses for existing drugs, through drug repurposing, can reduce the time,
costs, and risk of failure associated with new drug development. However, prioritizing drug …

Human diseases can be caused by complex mechanisms involving aberrations in numerous
proteins and pathways. With recent advances in genomics, elucidating the molecular basis …

Drug repositioning has been regarded as one of the most promising strategies for
translational medicine. Common efforts to find new uses for existing drugs depend on text …

Traditionally, most drugs have been discovered using phenotypic or target‐based screens.
Subsequently, their indications are often expanded on the basis of clinical observations …